{"id":"W3173401695","doi":"10.1158/1078-0432.ccr-21-0809","title":"5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":182,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche; Roche","keywords":"Vemurafenib; Medicine; Placebo; Internal medicine; Melanoma; Gastroenterology; Surgery; Metastatic melanoma; Pathology; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004473204,0.0007909725,0.00145634,0.0003195178,0.000558936,0.001172488,0.0005891771,0.001364947,0.002123832],"category_scores_gemma":[0.002609928,0.0002978542,0.003129702,0.0004361042,0.0004000083,0.0007556356,0.0005783974,0.001850259,0.000379168],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007335537,"about_ca_system_score_gemma":0.0006749931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001018151,"about_ca_topic_score_gemma":0.001755988,"domain_scores_codex":[0.9988715,0.0005640742,0.00008229022,0.0001988375,0.0001293253,0.0001540016],"domain_scores_gemma":[0.9970872,0.0004769037,0.001158238,0.0002711651,0.0001865047,0.0008200582],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7810377,0.00576015,0.1488336,0.0008591524,0.01108651,0.0003124931,0.0001844462,0.00263818,0.003812097,0.0001278682,0.004251615,0.04109614],"study_design_scores_gemma":[0.1610906,0.140846,0.6739036,0.0003416946,0.01335821,0.0007149058,0.0001243794,0.002681444,0.002066968,0.0003895334,0.004359004,0.0001236159],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911553,0.005306172,0.0002613336,0.0002349547,0.00008907547,0.000229522,0.001763268,0.00001882772,0.0009415654],"genre_scores_gemma":[0.9951874,0.0008045188,0.0001758687,0.0002814577,0.0001407416,0.0001847959,0.002647927,0.000005759885,0.0005716005],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004473204,"threshold_uncertainty_score":0.0236569,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0778736949624746,"score_gpt":0.4348568937526744,"score_spread":0.3569831987901998,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}